EUCTR2011-006280-21-BE进行中（未招募）1 期
Correlating the tumoral metabolic progression index measured by serial FDG PET-CT and apparent diffusion coefficient measured by MRI to patient's outcome in advance colorectal cancer - CORIOLA
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 53
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Participants must have histologically confirmed colorectal cancer that is metastatic or unresectable and for which standard treatments do not exist or are no longer effective.
- •Participants should be candidate for a Phase I study
- •The tumor should be refractory to all standard chemotherapy agents (fluoropyrimidines, irinotecan, and oxaliplatin) and anti-EGFR monoclonal antibodies in case of wild type K-ras (cetuximab or panitumumab) administered before study entry. Prior treatment with bevacizumab, regorafenib and/or aflibercept is allowed but not mandatory
- •Age equal or over 18 years.
- •Life expectancy of greater than 12 weeks.
- •ECOG performance status = 1.
- •Participants must have normal organ and marrow function as defined below:
- •Total bilirubin within 2 × normal institutional upper limits
- •AST/ALT/Alk Phosphatase levels < 5 × normal institutional upper limits
- •Creatinine within 2 × normal institutional upper limits or creatinine clearance > 35mL/min
- •Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and during the assessment. For women of child-bearing potential a pregnancy test (urinary or serum) must be performed within 7 days prior to inclusion and it must be negative. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician within one month.
- •Signed written informed consent obtained prior to any study specific screening procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 23
排除标准
- •Patients who exhibit any of the following conditions at screening will not be eligible for admission into the study:
- •Participants who have had chemotherapy or targeted therapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier.
- •Participants who have had a major surgery or radiotherapy within 4 weeks prior to entering the study.
- •Patients receiving any experimental agents during the assessment time period.
- •Patients with uncontrolled brain metastases.
- •Bleeding diathesis, history of cardiovascular ischemic disease or cerebrovascular incident within the last six months.
- •Uncontrolled concurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric illness or any significant disease which, in the investigator’s opinion, would exclude the patient from the study.
- •Pregnancy or breast-feeding before the FDG PET-CT scan examinations
- •Uncontrolled Diabetes.
- •Individuals with a history of a different malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.
- •Medical, geographical, sociological, psychological or legal conditions that would not allow the patient to complete the study or sign informed consent.
研究者
相似试验
进行中（未招募）
1 期
MOU-2017-01locally advanced resectable oesophago-gastric adenocarcinoma (Siewert I – III) with T3N0, T4N0, T2 – T4N+, stage Ib – IIIcMedDRA version: 21.0Level: PTClassification code 10030137Term: Oesophageal adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10001150Term: Adenocarcinoma gastricSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-001264-38-SKMasarykuv onkologický ústav70
已完成
不适用
Correlating the Tumoral Metabolic Progression Index to Patient's Outcome in Advanced Colorectal CancerColorectal CancerNCT01591590Jules Bordet Institute53
尚未招募
Unknown
Cross-sectional study on metabolic fate determination of brown adipose tissue and its impact on energy homeostasisJPRN-UMIN000053934Tohoku University1,200
招募中
不适用
Investigation of tumor evolution in sporadic and tumor disposition syndrome-associated tumorstumors in patients with a tumor predisposition syndromesporadic tumorsC00-C97D00-D09D10-D36D37-D48Malignant neoplasmsIn situ neoplasmsBenign neoplasmsNeoplasms of uncertain or unknown behaviourDRKS00030089niversitätsklinikum Augsburg, Medizinische Fakultät, Universität Augsburg2,000
尚未招募
1 期
The effect of cancer progression on the activity of the liver enzyme called CYP2C19 in patients with carcinoma of the gastrointestinal tract using the probe drug proguanil.Carcinoma of the gastrointestinal tractCancer - Other cancer typesACTRN12609000056291niversity of Auckland50